Viewing Study NCT07469956


Ignite Creation Date: 2026-03-26 @ 3:17 PM
Ignite Modification Date: 2026-03-26 @ 9:36 PM
Study NCT ID: NCT07469956
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-13
First Post: 2026-02-11
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sponsor: Sun Yat-sen University
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pancreatic Cancer Resectable View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Surufatinib View
None Toripalimab View
None Pancreatic cancer View
None Resectable View